RESPONSE-ADAPTIVE STEREOTACTIC BODY RADIOTHERAPY BOOST AFTER CONCURRENT CHEMORADIOTHERAPY IN UNRESECTABLE STAGE III NSCLC: A PROSPECTIVE SINGLE-CENTRE COHORT STUDY
In brief
Residual tumors receiving under 94.77 Gy had worse local control
In this prospective single-center cohort of 51 patients with unresectable stage III lung cancer, lower cumulative radiation dose to the residual primary tumor was associated with worse local control after an adaptive boost; 2-year local control was 62.8%. Distant spread remained the leading failure, and severe pneumonitis occurred in 7.8%, so local dose escalation alone may not address the main risk.
- Journal
- International journal of radiation oncology, biology, physics (Q1)
- Published
- 6 November 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 4, Very Low (CEBM 4)
- Authors
- Esin Kiraz, Celalettin Eroğlu, Mete Gündoğ, Oktay Bozkurt, Özgür Karabıyık, Ümmühan Abdülrezzak, et al.
- PMID
- 42994535
- DOI
- 10.1016/j.ijrobp.2026.10.041
Why clinicians should know about it
- Picked for Radiology, Radiation Oncology, Nuclear Medicine, Medical Physics and Imaging (paper of the day, 10 November 2026): Prospective adaptive SBRT boost with dose and outcome analysis
Abstract
OBJECTIVE: This study aimed to escalate the dose to the residual primary tumor with an adaptive stereotactic body radiotherapy (SBRT) boost after concurrent chemoradiotherapy (CRT) in unresectable stage III non-small cell lung cancer (NSCLC), and to explore, within this cohort, whether a higher cumulative dose to the residual primary was associated with better locoregional control (LRC) and whether this translated into a difference in overall survival (OS). MATERIALS AND METHODS: In this single-center, prospective, single-arm cohort, 51 patients received concurrent CRT (50 Gy/25 fractions with weekly carboplatin and paclitaxel) followed by an adaptive boost (30 Gy/5 fractions to the residual primary, 10 Gy/5 fractions to residual nodes), without consolidation durvalumab. Doses were summed by deformable registration and reported as EQD2. Response was assessed at 3 months with FDG-PET/CT (PERCIST), and toxicity with CTCAE v5.0. Outcomes estimated by Kaplan-Meier; predictors by Cox regression. RESULTS: At a median follow-up of 26 months, 2-year OS and LRC were 61.5% and 62.8%. The median PFS and DMFS were 13 and 16 months, and distant metastasis was the dominant failure pattern (41.2%). Cumulative dose below 94.77 Gy (EQD2) to the residual primary independently predicted worse LRC (HR 5.86), and a 3-month locoregional SUVmax ≥4.55 predicted worse LRC (HR 5.04). OS was independently associated with residual nodal volume, 3-month metabolic progression, and subsequent locoregional progression. Grade 3-4 pneumonitis occurred in 7.8%, grade 3 esophagitis in one patient (2%), and hemoptysis in five (9.8%). CONCLUSION: The SBRT boost achieved encouraging locoregional control, including in bulky and node-advanced disease, without immunotherapy, and higher cumulative dose to the residual primary was associated with better locoregional control. Hemoptysis was the main safety concern and occurred predominantly in patients with pre-existing hemoptysis, supporting careful selection and strict bronchial constraints. Local escalation alone did not overcome the competing risk of distant failure.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.